TOMS Founder Sold Company for $400 Million, Then Faced Misdiagnosis

Blake Mycoskie sold TOMS Shoes for $400 million. Then a psychiatrist told him he had bipolar disorder. He says the diagnosis was wrong — and that the misdiagnosis nearly cost him everything.

That sequence inverts the usual order of events. Most people land in a psychiatrist's office because something happened: a loss, a breakup, the end of a career. Mycoskie arrived after the biggest win of his professional life — the sale of the company he built — and walked out with a mental health label he now says was inaccurate.

The $400 million exit made Mycoskie one of the most prominent social entrepreneurs of his generation. TOMS built its brand on a one-for-one model: for every pair of shoes sold, the company donated a pair to a child in need. The sale price, the misdiagnosis, and the fallout that followed now form the core of the story Mycoskie is telling publicly.

The details he has shared are stark in their outline. A founder sells his company for $400 million. Shortly afterward, he receives a bipolar disorder diagnosis. He later concludes the diagnosis was wrong. And the consequences of that wrong label, by his own account, came close to costing him everything — a phrase that in his telling covers far more than money.

For an entrepreneur who had just completed a nine-figure liquidity event, the pattern is instructive. The sale of a company is routinely treated as the finish line: the moment risk converts to reward and the founder's problems end. Mycoskie's account argues the opposite. The exit itself became the trigger. What followed the sale — not the years of building it — pushed him into a psychiatrist's office.

The misdiagnosis compounds the problem. A wrong bipolar disorder label carries weight. It shapes how doctors treat a patient, what medications they prescribe, and how the patient understands his own mind. When the diagnosis is wrong, the treatment built on it misses the target. Mycoskie says the resulting damage extended to nearly every part of his life.

His story also exposes a gap in how the business world handles founders after they sell. Advisors surround entrepreneurs through diligence, negotiation and closing. Once the wire clears, the support structure dissolves. Mycoskie had $400 million and, by his own account, a psychiatric misdiagnosis that almost destroyed him. Those two facts coexisted.

The public telling matters on its own terms. When a founder of Mycoskie's profile says out loud that he was misdiagnosed with bipolar disorder after a $400 million exit and that it nearly cost him everything, he normalizes a conversation that usually stays private. Other founders who sell companies — and who struggle afterward in ways that confound their advisors — now have a named precedent.

It also puts pressure on how mental health care is delivered to high-achieving patients. A psychiatrist's office is usually the destination after a triggering event. Mycoskie's case suggests the trigger can be success itself, and that the diagnosis handed down in that office deserves the same scrutiny an entrepreneur would apply to any other professional advice.

Mycoskie has since reclaimed the narrative. His account now stands as a caution for founders approaching their own exits: the number on the wire transfer does not settle what comes next, and a wrong diagnosis after the deal can do more damage than any term sheet ever could.